The Relationship Between Hormone Receptor Status and C-erbB-2 Level with Treatment Results of 640 Breast Cancer Patients

被引:0
作者
Demircioglu, Fatih [1 ]
Pak, Yucel [2 ]
Akmansu, Muge [2 ]
Bora, Huseyin [2 ]
机构
[1] Rize Recep Tayyip Erdogan Univ, Egitim & Arastirma Hastanesi, Radyasyon Onkol, Rize, Turkey
[2] Gazi Univ, Tip Fak, Radyasyon Onkol, Ankara, Turkey
来源
GAZI MEDICAL JOURNAL | 2013年 / 24卷 / 03期
关键词
Breast neoplasm; hormone receptor status; c-erbB-2;
D O I
10.12996/gmj.2013.21
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: In this study the relevant factors that effects the treatment outcomes of patients like hormone receptor and c-erbB-2 was established. Methods: The overall and disease-free survival rates were evaluated in 640 breast cancer patients. The mean follow-up was 59,1 months. Overall and disease-free survival rates found by Kaplan-Meier method at SPSS version 16.0. Log-Rank test evaluated the prognostic factors impact. Results: In ER (+) and (-) patients 5 year overall survival rates was 85,7%, 71,2% (p<0,001), disease free survival rates was 79,9%, 63,7% (p<0,001) respectively; in PR (+) and (-) patients 5 year overall survival rates was 85,6%, 71,6% (p<0,001), disease free survival rates was 79,6%, 64,3% (p<0,001) respectively. ER and PR positivity were significantly increased overall and disease-free survival. In c-erbB-2 over-expression 5 year overall survival rates was 76,4%, 85,3% (p= 0,002), disease free survival rates was 69,7%, 79,1% (p=0,012) according to (-) patients. The worst prognosis had shown in ER (-), PR (-), c-erbB-2 (+) patients. Conclusion: ER, PR and c-erbB-2 levels have great importance in breast cancer and must be well considered in patients follow-up.
引用
收藏
页码:74 / 77
页数:4
相关论文
共 50 条
[21]   C-erbB-2 oncoprotein in the sera and tissue of patients with breast cancer. Utility in prognosis [J].
Molina, R ;
Jo, J ;
Filella, X ;
Zanon, G ;
Pahisa, J ;
Munoz, M ;
Farrus, B ;
Latre, ML ;
Gimenez, N ;
Hage, M ;
Estape, J ;
Ballesta, AM .
ANTICANCER RESEARCH, 1996, 16 (4B) :2295-2300
[22]   c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value [J].
Rafael Molina ;
Judith Jo ;
Xavier Filella ;
Gabriel Zanon ;
Jaume Pahisa ;
Montserrat Muñoz ;
Blanca Farrus ;
Maria Luz Latre ;
Carmen Escriche ;
Jordi Estape ;
Antonio M. Ballesta .
Breast Cancer Research and Treatment, 1998, 51 :109-119
[23]   Serial serum c-erbB-2 levels in patients with breast carcinoma [J].
Volas, GH ;
Leitzel, K ;
Teramoto, Y ;
Grossberg, H ;
Demers, L ;
Lipton, A .
CANCER, 1996, 78 (02) :267-272
[24]   Detection of urokinase plasminogen activator receptor and c-erbB-2 in sera of patients with breast and ovarian carcinoma [J].
Mabrouk, RAWR ;
Ali-Labib, R .
CLINICAL BIOCHEMISTRY, 2003, 36 (07) :537-543
[25]   Metastatic cancer cells from c-erbB-2 negative primary breast cancer maintain the original c-erbB-2/HIF1α phenotype [J].
Giatromanolaki, Alexandra ;
Koukourakis, Michael I. ;
Simopoulos, Costantinos ;
Sivridis, Efthimios .
CANCER BIOLOGY & THERAPY, 2007, 6 (02) :153-155
[26]   C-erbB-2: Expression in patients with breast carcinoma in comparison to patients with benign breast diseases [J].
Kalogeraki, A ;
Tzardi, M ;
Datseris, G ;
Kanavaros, P ;
Karvelas, C ;
Chalkiadakis, G ;
Tsiftsis, D ;
Delides, G .
ANTICANCER RESEARCH, 1996, 16 (02) :765-771
[27]   LEVEL OF C-ERBB2 IN SERUM AND SALIVA OF BREAST CANCER PATIENTS [J].
Sulistiowati, Eva ;
Haryono, Samuel .
BULETIN PENELITIAN KESEHATAN, 2014, 42 (04) :223-230
[28]   Molecular markers (c-erbB-2, p53) in breast cancer [J].
Agrawal, Anil Kumar ;
Jelen, Michal ;
Rudnicki, Jerzy ;
Grzebieniak, Zygmunt ;
Zukrowski, Piotr ;
Nienartowicz, Ewa .
FOLIA HISTOCHEMICA ET CYTOBIOLOGICA, 2008, 46 (04) :449-455
[29]   COMPARATIVE ANALYSIS OF ESTROGEN, PROGESTERONE, C-ERBB-2 RECEPTOR STATUS OF AGE MATCHED MALE AND FEMALE BREAST CARCINOMA [J].
Jamal, Shahid ;
Mubarik, Azhar ;
Mansoor, Alia ;
Mushtaq, Huma .
PAKISTAN JOURNAL OF MEDICAL SCIENCES, 2009, 25 (05) :806-810
[30]   The prognostic significance of c-erbB-2 serum protein in metastatic breast cancer [J].
Fehm, T ;
Maimonis, P ;
Katalinic, A ;
Jäger, WH .
ONCOLOGY, 1998, 55 (01) :33-38